Glaxo Wellcome Inc.

Smithkline Beecham Corporation

Glaxosmithkline LLC

The University of North Carolina at Chapel Hill

Burroughs Wellcome Co.

Novartis Vaccines & Diagnostics, Gmbh

North Carolina Central University

David Lee Musso

James L Kelley

David John Cowan

Barrett R Cooper

Michael Joseph Bishop

Jason Daniel Speake

Jeffrey Leaman Selph

John Joseph Partridge

Rodolfo Cadilla

Virgil L Styles

Marc W Andersen

Andrew Lamont Larkin

Dulce Garrido Bubacz

Paul Kenneth Spearing

Robert Carl Andrews

Gregory Cooksey Rigdon

Michael Howard Rabinowitz

Robert William Wiethe

Michael David Gaul

Joseph Howing Chan

Gary Martin Green

Daryl Lynn McDougald

Jennifer Badiang Stanford

Ed Williams McLean

Gloria Faye Orr

Phillip Frederick Morgan

Cunyu Zhang

Daniel T Chu

Aaron Matthew Smith

Stanley Dawes Chamberlain

Stephen Andrew Thomson

Rustum S Boyce

Natalia Aurrecoechea

Grady Evan Boswell

Holly Kathleen Emerson

Christopher R Conlee

Gregory Peckham

Brian D Thompson

Kien S Du

Jonathan Z Sexton

Judith De Armas Kuntz

Kevin K Barvian

William R Swain

Jay E Brenman

Brian A Chauder

The present invention provides compounds of Formula (I): wherein variables X, Y, Z and R1 are as described herein. Some of the compounds described herein are glutamate dehydrogenase activators. The invention is also directed to pharmaceutical compositions comprising these compounds, uses of these compounds and compositions in the treatment of metabolic disorders as well as synthesis of the compounds. 

Compounds useful for the treatment of metabolic disorders and synthesis of the same

Novel compounds which are antagonists or inverse agonists at one or more of the opioid receptors, pharmaceutical compositions containing them, to processes for their preparation.

Compounds as antagonists or inverse agonists of opioid receptors for treatment of addiction

Compounds as antagonists or inverse agonists at opioid receptors

A variety of small molecule, guanidine-containing molecules capable of acting as MC4-R agonists are provided. The compounds are useful in treating MC4-R mediated diseases when administered to subjects. The compounds have the structure IA, IB, and IC where the values of the variables are defined herein. 

Substituted quinazolinone compounds

A crystal structure of the cfms kinase domain, co-crystal structure with a bound small molecule, as well as methods of using the same in the discovery of cfms inhibitors and in the treatment of diseases mediated by inappropriate cfms activity.

Crystal structure of liganded cFMS kinase domain

Disclosed is the compound (+)-(2S,3S)-2-(3-chlorophenyl)-3,5,5-trimethyl-2-morpholinol and pharmaceutically acceptable salts and solvates thereof, pharmaceutical compositions comprising them, and processes for their preparation and use; also disclosed is a method of treating depression, attention deficit hyperactivity disorder (ADHD), obesity, migraine, pain, sexual dysfunction, Parkinson's disease, Alzheimer's disease, or addiction to cocaine or nicotine-containing (especially tobacco) products using such compound, salts, solvates or compositions.

Pharmaceutically active morpholinol

Disclosed is the compound (&plus;)-(2S,3S)-2-(3-chlorophenyl)-3,5,5-trimethyl-2-morpholinol and pharmaceutically acceptable salts and solvates thereof, pharmaceutical compositions comprising them; also disclosed is a method of treating depression, attention deficit hyperactivity disorder (ADHD), obesity, migraine, pain, sexual dysfunction, Parkinson's disease, Alzheimer's disease, or addiction to cocaine or nicotine-containing (especially tobacco) products using such compound, salts, solvates or compositions.

A family of compounds having the general structural formula

Formamide compounds as therapeutic agents

Disclosed is the compound (&plus;)-(2S,3S)-2-(3-chlorophenyl)-3,5,5-trimethyl-2-morpholino and pharmaceutically acceptable salts and solvates thereof, pharmaceutical compositions comprising them; also disclosed is a method of treating depression, attention deficit hyperactivity disorder (ADHD), obesity, migraine, pain, sexual dysfunction, Parkinson's disease, Alzheimer's disease, or addiction to cocaine or nicotine-containing (especially tobacco) products using such compound, salts, solvates or compositions.

Novel compounds of formula (1) together with their salts and solvates have a number of uses in medicine, in particular as central muscle relaxants.

Bicyclic amide derivatives and their use as muscle relaxants

Amide derivatives and their therapeutic use

Novel (2S, 3S, 5R) morpholinols of formula (I) ##STR1## together with the (+-)-(2R*,3R*,5S*) racemates thereof, and their salts, wherein

Heterocyclic pharmaceutical compounds and use

Growing community of inventors

Raleigh, NC, United States of America

David Lee Musso